The Covid crash continues
Pfizer keeps declining, but it is not the only pandemic player to suffer.
Biopharma stocks go back to bleak
Hopes for a better 2023 look optimistic as markets take another turn for the worse.
Go or no go? Overcoming delays
US Pdufa decisions loom for Apellis and Travere, while Menarini and Lilly got their approval firsts already.
Go or no go? Pdufa resolutions eyed for J&J and Amryt
February will also see an outcome for Gilead's long-acting HIV therapy, and a key FDA panel for me-too checkpoint MAbs.